We are live on
!
Find out more
AVLSA
Atlas Venture Life Science Advisors Portfolio holdings
AUM
$790M
1-Year Est. Return
223.66%
This Fund
S&P 500
This Quarter
Est. Return
+53.48%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
+$244M
(+29%)
Cap. Flow
-$76.9M
Cap. Flow
% of AUM
-7.1%
Top 10 Holdings %
Top 10 Hldgs %
96.51%
Holding
17
New
1
Increased
–
Reduced
7
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Q32 Bio
QTTB
|
+$28.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dyne Therapeutics
DYN
|
+$42.2M |
| 2 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$17.6M |
| 3 |
Disc Medicine
IRON
|
+$17.4M |
| 4 |
Kymera Therapeutics
KYMR
|
+$17.2M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$8.39M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Dyne Therapeutics
DYN
$4.69B
| $228M | 21.01% |
8,020,136
-1,865,313
| -19% | -$42.2M |
|
|
2
Kymera Therapeutics
KYMR
$8.26B
| $216M | 19.95% |
5,377,362
-480,900
| -8% | -$17.2M |
|
|
3
Disc Medicine
IRON
$2.91B
| $142M | 13.14% |
2,287,233
-267,939
| -10% | -$17.4M |
|
|
DAWN
4
DELISTED
Day One Biopharmaceuticals
DAWN
| $106M | 9.8% |
6,430,257
-1,178,137
| -15% | -$17.6M |
|
|
THRD
5
DELISTED
Third Harmonic Bio
THRD
| $103M | 9.5% |
10,907,859
| – | – |
|
6
Korro Bio
KRRO
$154M
| $101M | 9.3% |
1,119,292
| – | – |
|
|
JBIO
7
Jade Biosciences
JBIO
$1.16B
| $60.3M | 5.57% |
58,264
| – | – |
|
|
8
Q32 Bio
QTTB
$458M
| $35.6M | 3.29% |
+2,092,106
| New | +$28.8M |
|
|
GBIO
9
DELISTED
Generation Bio
GBIO
| $33.7M | 3.11% |
827,948
| – | – |
|
|
VIGL
10
DELISTED
Vigil Neuroscience
VIGL
| $19.9M | 1.84% |
5,836,874
| – | – |
|
11
Replimune Group
REPL
$1B
| $17.1M | 1.58% |
2,098,300
| – | – |
|
|
IMA
12
ImageneBio Inc
IMA
$65.2M
| $7.13M | 0.66% |
418,182
| – | – |
|
|
TECX
13
Tectonic Therapeutic
TECX
$526M
| $5.81M | 0.54% |
378,448
| – | – |
|
14
Dianthus Therapeutics
DNTH
$5.73B
| $5.61M | 0.52% |
186,979
-50,000
| -21% | -$1.09M |
|
15
Xilio Therapeutics
XLO
$59.4M
| $1.07M | 0.1% |
70,922
-126,174
| -64% | -$1.22M |
|
16
Spero Therapeutics
SPRO
$66.6M
| $1.05M | 0.1% |
607,613
-405,825
| -40% | -$636K |
|
|
AKRO
17
DELISTED
Akero Therapeutics
AKRO
| – | – |
-359,251
| Closed | -$8.39M |
|
Similar funds
AWG
AT
MTWSIF
VH
M
AI
VCM
SWIG
Atlas Venture Life Science Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, Atlas Venture Life Science Advisors held 17 positions worth $1.08B, up 29% from $840M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Atlas Venture Life Science Advisors withdrew a net $76.9M in Q1 2024, closing 1 position and reducing 7 holdings. Its most notable exit was Akero Therapeutics, an estimated $8.39M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Atlas Venture Life Science Advisors opened a new position in Q32 Bio worth $35.6M.
- Atlas Venture Life Science Advisors's largest Q1 2024 buy was Q32 Bio: 2,092,106 shares worth $35.6M.
- Atlas Venture Life Science Advisors's biggest Q1 2024 reduction was Dyne Therapeutics, cutting an estimated $42.2M.
- Atlas Venture Life Science Advisors fully exited Akero Therapeutics in Q1 2024, selling an estimated $8.39M.
- Atlas Venture Life Science Advisors's ten largest holdings make up 97% of its $1.08B portfolio in Q1 2024.
- Atlas Venture Life Science Advisors opened 1 new position and closed 1 in Q1 2024.
- Atlas Venture Life Science Advisors's portfolio value rose 29% quarter-over-quarter to $1.08B.
Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2024, filed 6 May 2024.